Mr. Pink's Picks: selected event-driven value investments Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Mr. Pink's Picks: selected event-driven value investments

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TRIIBoy who wrote (13289)	4/26/2000 4:33:00 AM
From: Doc Bones	Read Replies (1) of 18998

CELG was reprimanded because their salesmen were advising doctors that Thalidomide could be used against multiple myeloma, a deadly cancer with little in the way of treatment available. This is in fact against FDA rules, although studies not yet finalized have been very promising: "Progress in the treatment of multiple myeloma over the past two decades has really been minimal. From that standpoint, these findings would have to be considered quite encouraging", says Harmon Eyre of the American Cancer Society." Message 11223137 Message 11818468 Message 13485116 -------- CELG has a number of other very promising drugs in development, a recently completed $300 Million secondary offering, and the backing of a "murderers' row" of SI biotech sluggers. I got lucky, and panicked into a pretty good sale price after the peak, so you won't affect me. But I have to think there are better shorts out there. Doc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next